Kite Flies CAR-T Into Asia With Daiichi Sankyo, Fosun Deals
Now that Kite Pharma Inc.’s first chimeric antigen receptor T cell (CAR-T) therapy axicabtagene ciloleucel (KTE-C19) is being submitted for US FDA approval, Chairman, President and CEO Arie Belldegrun said it is the right time to think about ways to make the company’s technology available in additional markets, like Japan and China where Kite entered into partnership agreements with Daiichi Sankyo Co. Ltd. and Shanghai Fosun Pharmaceutical Group Co. Ltd., respectively.
You may also be interested in...
The UK cell therapy biotech ReNeuron has attracted the healthcare group, Fosun Pharma, which is building up a leading position in regenerative medicine, to develop and commercialize its products in China.
Daiichi teams with Glycotope on an antibody-drug conjugate for cancer, while Alector will partner with AbbVie to research antibody targets for Alzheimer’s disease.
The approval of Kite's Yescarta has ignited Chinese drug maker Fosun. With a joint venture with Kite in place, the Shanghai conglomerate is looking to accelerate CAR-T development in China despite approval pathway uncertainty.